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Evidence is mounting that a multi-gene kinase network
is central to the regulation of renal Naþ and Kþ excretion
and that aberrant signaling through the pathway can
result in renal sodium retention and hypertension (HTN).
The kinase network minimally includes the Ste20-related
proline–alanine-rich kinase (SPAK), the with-no-lysine kinases
(WNKs), WNK4 and WNK1, and their effectors, the thiazide-
sensitive NaCl cotransporter and the potassium secretory
channel, ROMK. Available evidence indicates that the kinase
network normally functions as a switch to change the
mineralocorticoid hormone response of the kidney to either
conserve sodium or excrete potassium, depending on
whether aldosterone is induced by a change in dietary
sodium or potassium. Recently, common genetic variants in
the SPAK gene have been identified as HTN susceptibility
factors in the general population, suggesting that altered
WNK–SPAK signaling plays an important role in essential
HTN. Here, we highlight recent breakthroughs in this
emerging field and discuss areas of consensus and
uncertainty.
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Hypertension (HTN) is a substantial public health problem,
affecting over a billion people on the planet. It is a major
independent risk factor for myocardial infarction, stroke, and
end-stage renal disease. The pathogenesis of essential HTN
remains unknown, but epidemiological studies point to
complex genetic and environmental factors. Genes have a
major role in HTN susceptibility, with the heritability of
blood pressure (BP) levels estimated to be 30–35%. Major
environmental triggers include obesity and diet, especially
high Naþ and low Kþ dietary intake. The recent discovery
of Ste20-related proline–alanine-rich kinase (SPAK, also
known as serine threonine kinase 39 or STK39) as a HTN
susceptibility gene in the general population,1 together with
the known involvement of with-no-lysine (WNK) kinases
in a rare familial disorder of HTN and hyperkalemia,
now casts light on the potential importance of a multi-gene
kinase network in the genesis of HTN. In fact, a flood
of recent studies are beginning to shed light on the
mechanisms by which dietary salt intake influences renal
Naþ transport and how mutations in these kinases and
ion transport genes may lead to BP dysregulation. The
objective of this minireview is to highlight recent break-
throughs and to discuss areas of consensus and uncertainty
in this emerging field.
THE ROLE OF THE KIDNEY IN HTN
Physiologists have long appreciated the central role of
renal salt excretion in the control of BP.2 Maintenance
of a constant intravascular fluid volume and BP depends on
the ability of the kidneys to regulate urinary Naþ excretion.
The concerted action of several parallel Naþ transport
mechanisms allows urinary Naþ excretion to match a
wide range of Naþ dietary intakes, while minimizing
fluctuations in the intravascular fluid volume and arterial
BP. Although the abnormal function of any one renal salt
transport mechanism can usually be compensated for, a
greater than normal increase in arterial BP must occur in
order for urinary Naþ excretion to be brought into balance
with an increased Naþ intake. Guyton2 coined the term for
this change in BP as the ‘set-point’ for controlling Naþ
excretion.
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GENETIC EVIDENCE LINKING RENAL SALT HANDLING TO BP
REGULATION
Mutations in B20 different genes have been linked with
known single-gene forms of hereditary HTN or hypo-
tension.3 Astonishingly, all of these genes encode molecules
that control the ability of the kidney to maintain salt balance,
reiterating the importance of this physiological pathway in
regulating BP. The distal Naþ channel (epithelial sodium
channel (ENaC)) and the thiazide-sensitive NaCl cotran-
sporter (NCC) have a central role in BP regulation. Loss-
of-function mutations in ENaC can cause the hypotension
of pseudohypoaldosteronism (PHA) type I, while gain-of-
function mutations result in HTN (Liddle’s syndrome). Loss-
of-function mutations in NCC cause Gitelman’s disease,4
an autosomal recessive salt-losing nephropathy characterized
by hypotension, hypokalemic metabolic alkalosis, and
altered divalent cation homeostasis. Conversely, HTN in
PHA type II (Gordon’s syndrome) ultimately results from a
gain-of-function by NCC. This rare autosomal dominant
disease of HTN and hyperkalemia results from mutations
in two WNK genes, WNK1 and WNK4.5 In the general
population, rare heterozygous loss-of-function mutations
in NCC produce clinically significant reductions in BP
and protection from HTN.6 Moreover, studies from the
Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial, the largest clinical BP-lowering trial in
history, clearly demonstrated the morbidity- and mortality-
lowering benefits of inhibiting NCC in the treatment of
essential HTN.7 Together with recent genome-wide asso-
ciation studies identifying an important kinase regulator of
renal salt transport, SPAK, as a HTN susceptibility gene,1 it
seems likely that essential HTN may be born out of a
combination of common and rare susceptibility alleles that
affect the ability of the kidney to appropriately respond to
dietary salt.
SENSITIVITY TO DIETARY Naþ AND Kþ
As predicted by the Guyton model, dietary salt (NaCl)
loading is well established to increase BP in humans. The best
evidence comes from tightly controlled, dose–response trials
in large populations. For example, the Dietary Approaches to
Stop HTN trial convincingly revealed a dose-dependent
decrease in BP in response to Naþ reduction regardless of
whether the subjects were hypertensive or nonhypertensive.8
It should be pointed out that the reduction in BP is
heterogenous,9 with individuals exhibiting a continuous
spectrum of responses to a reduction in dietary Naþ . In
general, the effect of Naþ on BP is greatest in Blacks and in
individuals with chronic kidney disease or HTN. Thus, it is
not just dietary Naþ that determines BP, but genetic and
other factors also have an important impact.10 One of the
most important of these other factors is dietary Kþ .11 High
dietary Kþ intake is associated with reduced BP. Further-
more, the rise in BP for a given increase in Naþ intake is
blunted in the setting of a high Kþ intake. For these reasons,
recommended dietary regimens to reduce HTN, such as that
recommended by the Dietary Approaches to Stop HTN trial,
provide a relatively high level of Kþ .10
The scientific basis for the response to Kþ is not under-
stood. However, the discovery that the WNK–SPAK kinase
network regulates renal Naþ and Kþ transport provides a clue
that the impact of Kþ diet on BP might be due to a physio-
logical switch that alters the response of the kidney to either
conserve Naþ or excrete Kþ , depending on whether secretion of
the mineralocorticoid hormone, aldosterone, is induced by a
change in dietary Naþ or Kþ . How renal Naþ reabsorption
and Kþ excretion are coordinately regulated has long been a
puzzle because aldosterone controls both processes. In states of
intravascular volume contraction (for example, low-Naþ diet),
angiotensin II (AngII) stimulates aldosterone release to maximize
renal NaCl reabsorption and restore BP. On the other hand,
when aldosterone is released in response to a rise in plasma
Kþ (for example, high-Kþ diet), it stimulates maximum
Kþ excretion without major effects on renal Naþ handling.
Studies on how pseudohypoaldosteronism II (PHAII)
causes both HTN and hyperkalemia have cast light on how
the kidney responds appropriately to aldosterone. Patients
with the disease exhibit both excessive Naþ retention and
impaired Kþ excretion despite normal aldosterone and
otherwise normal renal function. The discovery that muta-
tions in WNK1 or WNK4 cause PHAII5 revealed a signaling
system that may switch the balance between Naþ reabsorp-
tion and Kþ excretion. In PHAII, mutations appear to
aberrantly switch the kinases into the ‘hypovolemia’ position
and divorce the system from physiological control, causing
deleterious Naþ and Kþ retention regardless of volume or
Kþ status. Although concepts about WNK signaling in the
kidney are still emerging, present evidence suggests that the
WNK kinases converge with the SPAK kinase to switch
the mineralocorticoid hormone response of the kidney to
be either Naþ retaining (antinatriuretic) or Kþ excreting
(kaliuretic). This likely occurs because the kinase pathway
differently regulates the thiazide-sensitive Naþ chloride
cotransporter, NCC,12 and the Kþ excretory channel, ROMK
(Renal Outer Medullary K channel, Kir 1.1)13 (Figure 1).
REGULATION OF NCC BY THE WNK–SPAK SWITCH
NCC is the principal determinant of renal NaCl reabsorption
in the distal convoluted tubule (DCT).14 It is tightly regulated
by aldosterone and AngII, allowing Naþ reabsorption in the
DCT to be modulated in accord with the demands of salt
balance and intravascular pressure. Multiple studies suggest
that members of the WNK kinase family converge with SPAK
or possibly the related kinase, oxidative stress response kinase
1 (OSR1), to transmit and integrate the aldosterone and
AngII response by controlling NCC transport activity.15,16
Work in model systems and genetically engineered mouse
models revealed that wild-type WNK4 has the capacity to
reduce NCC expression at the plasmalemma. As PHAII
missense mutations in WNK4 (WNK4PHAII) block this
inhibitory activity,17,18 the apical expression and activity of
the transporter are considered to increase in the disease.
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Moreover, a WNK4PHAII mouse model shows stimulation of
SPAK/OSR1-dependent phosphorylation of NCC to enhance
transport activity.19 Both factors—increased apical mem-
brane expression and increased activity of NCC—likely
explain Naþ retention in PHAII. The effects of WNK4 on
ROMK are somewhat more controversial20 (also see below),
but early work in model systems indicated that WNK4PHAII
mutations affect ROMK in an opposite manner to that of
NCC. Consequently, Kahle et al.21 postulated that WNK4
might physiologically shuttle between two states. They
suggested that if WNK4 switched from its basal state to a
mode that is mimicked by WNK4PHAII, it would tune the
aldosterone response such that normally it restores intra-
vascular volume without perturbing Kþ balance.
The physiological mediators of the putative WNK4 switch
have only begun to be identified, but recent work highlights
the importance of AngII. As AngII levels are high in the
hyperaldosterone state of hypovolemia (or low-salt diet) but
are low in hyperkalemia, signaling through the AngII
receptor, AT1R, has been a chief suspect in switching
WNK4 into a mode that simultaneously activates NCC and
inhibits ROMK. Consistent with this idea, AngII stimulates
NCC22 and inhibits ROMK in vivo.23 Exciting recent studies
reveal that AngII stimulation of NCC can be reconstituted in
Xenopus oocytes when WNK4 and SPAK are included in the
system.24 Together with observations that AngII signaling
increases phosphorylation of key sites on SPAK and NCC in a
WNK4-dependent manner, it is likely that WNK4–SPAK is
the chief arbiter of the signaling pathway between AT1R and
NCC. According to this model, activation of the AT1R
pathway converts WNK4 from an inhibiting mode to an
NCC-activating form (Figure 1). The activating form of
WNK4 induces a phosphorylation cascade, whereby WNK4
phosphorylates SPAK and then phospho-SPAK phosphor-
ylates and activates NCC. The stimulatory effects of mutant
WNK4PHAII are not augmented by AngII, consistent with the
mutations having a gain-of-function effect resulting in
constitutive activation of the signaling pathway.
Unlike WNK4, WNK1 is not able to mediate the AT1R
signaling response.24 However, under certain conditions,
such as osmotic stress, WNK1 can phosphorylate and activate
SPAK.25,26 On the basis of these observations, it seems
reasonable to hypothesize that a WNK1-dependent SPAK
activation pathway may also be involved in stimulating NCC
under certain physiological settings. Work in cell culture
systems indicates the involvement of the PKB/PI3-kinase
signaling pathway in activating WNK1.27,28 Such a pathway
may be responsible for linking insulin to the regulation of
NCC,29 but thus far suitable studies rigorously connecting
these observations are lacking. To date, attention has largely
focused on the ability of WNK1 isoforms to regulate NCC
through their modulation of WNK4 (see below).
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Figure 1 |Model of the WNK–SPAK signal transduction system in the distal nephron, switching the aldosterone response of the
kidney to be antinatriuretic (left) or kaliuretic (right). Green arrowheads (activating pathways), red blunt end (inhibitory pathway).
The left panel shows the pathway in the setting of a low-Naþ diet, when AngII and SGK-1 signaling leads to phosphorylation of WNK4.
This stimulates phosphorylation of SPAK, which, in turn, phosphorylates NCC, activating Naþ transport to enhance conservation of Naþ
in hypovolemia. Stimulation of unknown receptors is suspected to cause phosphorylation of L-WNK1, which can also stimulate SPAK
phosphorylation. L-WNK1 has other functions: (a) It blocks the NCC-inhibitory form of WNK4. (b) It inhibits secretion of Kþ via ROMK
channels, so as to conserve Kþ despite high aldosterone levels. The right panel shows the pathway in the setting of high dietary Kþ intake,
when aldosterone is stimulated and AngII is low. In the absence of sufficient AngII, AT1R cannot activateWNK4. This reduces SPAK activation
and NCC phosphorylation. At the same time, dietary potassium loading increases the level of KS-WNK1 isoform to suppress the activity of
L-WNK1. Consequently, the full inhibitory power of WNK4 on NCC becomes unleashed, blocking traffic of NCC to the apical membrane and
thereby reducing NCC surface density. KS-WNK1 also blocks the effect of L-WNK1 on ROMK endocytosis, causing ROMK to increase at the
apical membrane. In this way, Kþ secretion in the DCT and connecting tubule/cortical collecting duct is maximized, whereas NCC is
suppressed. Aldosterone stimulation of ENaC (not shown) offsets the decreased Naþ reabsorption by NCC, allowing robust potassium
secretion without changes in sodium balance. (WNK3, which is believed to antagonize the inhibitory effects of WNK4 on NCC, and the
possible effects of WNK4 on ROMK are not shown for clarity.) DCT, distal convoluted tubule; NCC, NaCl cotransporter; ROMK, Renal Outer
Medullary K channel, Kir 1.1.
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In fact, WNK4 appears be a focal point of regulation by
other kinases as well.30–33 WNK4 has been shown to form
heteroligomeric complexes with WNK3 and L-WNK1.31,34
Functionally, WNK3 enhances the transport activity of
NCC31,35 through a SPAK-independent phosphorylation
mechanism,36 whereas L-WNK1 has antagonistic effects on
the NCC-inhibitory form of WNK4 (see below). Such
interactions between different WNKs have been suggested
to allow the signal transduction pathway to be precisely
tuned to meet the different physiological demands of
salt balance.31 Moreover, recent studies in heterologous
expression systems and knockout mice indicate that the
aldosterone-induced kinase, SGK-1, modulates WNK4 acti-
vity so as to increase NCC abundance, phosphorylation, and
activity.30,32,37 Two SGK phosphorylation sites have been
identified in the C-terminal of WNK4.30,32 As studied in the
oocyte expression system, phosphorylation of WNK4 at
these sites blocks the ability of WNK4 to inhibit NCC.32
Importantly, C-terminal phosphorylation of WNK4 does not
mimic the stimulatory effects of AngII.24 Instead, the AngII
signaling pathway appears to stimulate the WNK4 kinase
activity needed to phosphorylate SPAK.38 The precise
mechanism by which AngII turns on WNK4 is unknown,
but is likely to involve phosphorylation of the T-loop site in
the WNK4 kinase domain. The dual requirement for both
SGK-1 and ATR1 signaling to switch WNK4 from being an
inhibitor to an activator of NCC would provide a mechanism
to integrate the effects of high aldosterone and AngII for
appropriate activation of NCC in hypovolemia. It would also
explain why high aldosterone and SGK activation induced by
a high-K diet does not stimulate NCC transport, in which
case AngII is not elevated (see below).
It should be pointed out that an important detail of the
model has recently been called into question. On the basis of
the finding that NCC protein abundance is not augmented in
genetically modified WNK4 mice, which bear a targeted
deletion of exons 7–8, it has been argued that WNK4 may not
usually function as an inhibitor of NCC in vivo.39 In fact,
because these mice show reduced NCC phosphorylation and
a reduced renal Naþ reabsorptive capacity, a case has been
made for the idea that WNK4 only operates as an activator of
NCC in vivo. According to this view, WNK4PHAII mutations
only enhance the normal activity of the kinase.
Although these new studies with the so-called hypo-
morphic WNK4 mice are very interesting and should not be
dismissed, they are difficult to square with numerous reports
that WNK4 can inhibit NCC.17,18,24,34,40,41 Even a modest
overexpression of two extra WT WNK4 transgenes leads to a
dramatic decrease in NCC in vivo.42 Furthermore, RNA
interference-mediated knockdown of endogenous WNK4 in
human embryonic kidney cells increases NCC.43 In our
opinion, the switch model shown in Figure 1 provides a
way to reconcile the different findings, but several key
issues must be carefully examined. The major one is to test
what function is carried out by exons 7 and 8. It is
conceivable, for example, that this region of the kinase is not
required for the inhibitory effects of WNK4. The switch
model points to another possibility. To date, only the NCC
activation limb—low-salt diet—has been tested in WNK4
hypomorphic mice. It will be important to study whether
these mice also lose their ability to downregulate NCC
in physiological settings such as in hyperkalemia37 as the
model predicts.
WNK REGULATION OF Kþ BALANCE
The physiological uncoupling of aldosterone-dependent Kþ
secretion from Naþ reabsorption has been traditionally
explained by the Naþ and flow-dependent nature of Kþ
excretion. In states of intravascular volume depletion, for
example, stimulation of NCC at the DCT should diminish the
flow and supply of Naþ that can be delivered downstream to
the connecting tubule and cortical collecting duct for efficient
Naþ /Kþ exchange, mediated by the epithelial Naþ channel,
ENaC, and the Kþ secretory channels, ROMK and BK.44 In
states of antidiuresis, antidiuretic hormone stimulates ROMK
to maintain potassium secretion in spite of the decrease in
distal flow. However, the textbook explanation is not
completely satisfactory. It does not adequately explain how
the kidney stimulates maximum Kþ excretion without major
effects on renal Naþ handling when aldosterone is elevated
by increases in plasma Kþ . The classic teaching also
overlooks that a significant fraction of Kþ secretion likely
occurs in the late DCT, especially when animals are fed a
high-Kþ diet. In fact, a Kþ -secretory pathway that is not
dependent on ENaC has recently been described.45 Accumu-
lating evidence favors the idea that a WNK signaling pathway
may operate in parallel with the classic factors to achieve a
robust kaliuretic response to a Kþ load without altering Naþ
balance.
The signaling response to Kþ is just beginning to be
unraveled. L-WNK1, WNK3, and WNK4 all downregulate
ROMK at the cell surface in heterologous expression systems,
likely by stimulating clathrin-dependent endocytosis. But, so
far, only one WNK gene has emerged as a significant player
in vivo. Studies in genetically modified WNK4 mice,19,42 for
example, have been interpreted to indicate that WNK4 may
not have a role in the physiological regulation of ROMK, but
further studies with better, more specific ROMK antibodies
and definitive tests of ROMK function (for example, patch-
clamp analysis and measurements of potassium secretion in
preparations such as the isolated perfused tubule, in which
confounding variables can be tightly controlled) are despe-
rately required to test this hypothesis rigorously. WNK3 is
not associated with PHAII and its physiological relevance in
Kþ balance has not been studied. By contrast, accumulating
evidence indicates that products of the WNK1 gene are likely
to operate as a key arbiter of the switch response to Kþ diet.
Alternative promoter usage of the WNK1 gene produces a
kidney-specific short form of WNK1,46,47 called KS-WNK1,
and a more ubiquitous long form, called L-WNK1. Unlike
L-WNK1, the kinase-deficient KS-WNK1 form has no inhi-
bitory effect on ROMK.48,49 Instead, KS-WNK1 negatively
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modulates L-WNK1 to suppress ROMK channel endocytosis.
In fact, the apical surface expression of ROMK in the distal
nephron is enhanced in transgenic mice that overexpress
KS-WNK1.50 Most importantly, the relative abundance of the
WNK1 isoforms is regulated by dietary Kþ . As acute dietary
Kþ loading increases the relative abundance of KS-WNK1,
while dietary Kþ restriction increases the relative abundance
of L-WNK1, the WNK1 isoform switch is well positioned to
serve an important role in the physiological regulation of
ROMK apical surface density and Kþ balance.48,49
Importantly, the two WNK1 isoforms regulate NCC in a
manner different from that of ROMK, providing a mecha-
nism to maintain Naþ balance in the high-aldosterone state
of dietary Kþ loading. Heterologous expression studies
reveal that L-WNK1 upregulates NCC by blocking the
inhibitory form of WNK4. KS-WNK1, on the other hand,
antagonizes the effects of L-WNK1 and therefore indirectly
inhibits NCC.40 Consequently, the full inhibitory power of
WNK4 on NCC may become unleashed in states of dietary
Kþ loading, when KS-WNK1 expression is augmented. As
the high-aldosterone state associated with a high-K diet
stimulates SGK-1, the latter would act on ROMK to promote
K secretion.30,51 However, in the absence of AngII, the SGK
phosphorylation of C-terminal sites described above would
be insufficient to switch WNK4 into its kinase-active form
necessary for SPAK activation and NCC phosphorylation.
The functional significance of downregulation of NCC in the
hyperaldosterone state of high dietary Kþ together with
inhibition of Naþ transport in the thick ascending limb52
would be to counterbalance the enhanced ENaC-dependent
Naþ reabsorption in the connecting tubule and cortical
collecting duct, and thereby preserve Naþ homeostasis.
Thus, a main prediction of the linkage between Kþ and Naþ
balance is based on whether transport by NCC is down-
regulated in response to dietary Kþ loading as illustrated
in Figure 1. Recent studies have indeed shown that the
expression and phosphorylation of NCC are reduced by a
high-Kþ diet.37
Recent studies reveal a potential mechanism to explain
how WNKs regulate NCC and ROMK differently, involving
modulation of two distinct trafficking pathways. ROMK
contains an unusual variant of the ‘NPXY’ internalization
signal, which serves as a docking site for the clathrin adaptor
molecule, ARH (autosomal recessive hypercholesterolemia).53
WNK1 stimulates ROMK endocytosis through an ARH-
dependent pathway. Unlike ROMK, NCC does not contain
NPXY-type signals and, therefore, does not have the capacity to
engage ARH. In fact, Subramanya et al.43 recently discovered
that WNK4 does not stimulate NCC endocytosis. Instead,
WNK4 acts on newly synthesized NCC in the secretory
pathway to stimulate interaction with the AP-3 clathrin adaptor
and divert the transporter into the lysosomal pathway.
SPAK REGULATION
SPAK was identified as a membrane-associated kinase that
interacts with cation-chloride cotransporters and WNKs.54
Since this discovery in 2002, work in expression systems and
model organisms has clearly established that SPAK directly
regulates members of the electroneutral cation-chloride
cotransporter gene family, including NCC, as a part of an
evolutionarily conserved signaling pathway that is important
for controlling electroneutral Naþ transport and osmotic cell
volume regulation.55 The discovery of SPAK as a HTN
susceptibility gene highlights its potential role in the
regulation of renal Naþ transport for the control of BP.
On the basis of recent studies, a working model for NCC
activation in the kidney (Figure 1) envisages an upstream
WNK (either WNK4 or WNK1) phosphorylating and
activating SPAK, which in turn phosphorylates and activates
the cotransporter. The model is largely based on biochemical
studies in expression systems showing that WNK1 or WNK4
directly interacts with SPAK and phosphorylates residues
T243 and S383 (mouse numbering).38 Although the func-
tional role of S383 phosphorylation is still not known,
phosphorylation of T243 is absolutely required for SPAK
activation.56 Furthermore, activation of the WNK4–SPAK
signaling system in DCT cells in vitro by hypotonic stress or
AngII induces phosphorylation of NCC.24 Obviously, future
studies are required to test the validity of this model in vivo.
The exclusivity of SPAK in the proposed model has not
been established. SPAK is closely related to OSR1, which,
similar to SPAK, is widely expressed in many tissues,
including the kidney.57 SPAK is believed to have evolved
from OSR1 by gene duplication.55 OSR1 can also be activated
by WNKs and can phosphorylate NCC.25,26 Although it
might be imagined that OSR1 could substitute for SPAK, no
change in OSR1 expression is found in SPAK-null animals or
when SPAK is knocked down by RNA interference.58
Moreover, eliminating SPAK from cells that normally express
both SPAK and OSR1 results in a distinct impairment of
cotransporter function. Thus, SPAK and OSR1 are regulated
independently and may have distinct functional roles,
although the exact nature of their roles remains to be
defined. In addition, there are reports that signaling via PKC
isotypes can activate SPAK in other systems.59,60 Although
such a role in the kidney has not been evaluated, it is possible
that renal SPAK activity is also regulated via non-WNK
pathways.
FUTURE STUDIES
Although the scheme described in Figure 1 synthesizes much
of the currently available data to present a unified mechanism
for SPAK–WNK control of Naþ–Kþ balance and BP, we
consider it as an evolving model and as only a framework for
guiding future investigation. Certainly, much of the model
needs to be rigorously tested, and much will be learned in
the process. In our opinion, a convergence of powerful
approaches addressing this problem can promise to rapidly
yield a comprehensive and clinically useful understanding of
multigene kinase control of BP in health and disease.
Central to this advance will be genetically modified mouse
models that either eliminate or modify kinases of interest.
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Despite being a critical and powerful approach, such studies
need to be interpreted carefully, as the kidney has a strong
ability to compensate for defective or missing components.
Thus, testing the physiological validity of findings from
mouse models will require carefully performed parallel
studies in normal animals. Evaluation of the effects of
altered Naþ and Kþ diet on the status of switch elements
together with measurements of Naþ and Kþ transport
in vivo and in isolated perfused tubules should be particularly
informative.
Although carefully performed animal studies are neces-
sary, important, and insightful, they may not offer detailed
insights into the underlying cellular, biochemical, and
molecular mechanisms. An exhaustive mechanistic analysis
will require further investigation in model systems, including
oocytes and cultured cells. For such studies, it will be critical
to complement and validate the standard kinase over-
expression experiments with RNA interference-mediated
knockdown approaches. It should be particularly instructive,
for example, to replace endogenous components of the
signaling pathway with physiological doses of strategically
designed mutants. Vigilant monitoring of the subcellular
localization and phosphorylation status of the relevant
parts of the signaling network will be crucial to guide
interpretation.
Continued genetic analysis in humans promises to be a
crucial arm of a multidisciplinary investigation, serving to
identify additional variants that influence BP. This approach
has been highly successful for rare alleles, but association
findings for common alleles have been much less consistent.
Earlier genome-wide SNP arrays offered uneven and
incomplete coverage of variants in genes in this network,
particularly WNK4.61 Studies that focus on a single gene or
on a few genes often consider different SNPs, making cross-
validation a challenge. However, the tide is rapidly turning.
Currently, newer arrays offer more complete coverage. Data
from multiple studies can be more easily combined
(4100,000 total subjects) or filled in through imputation,
making it likely that the next generation of genome-
wide association studies will yield additional insights.62,63
With the application of new high-throughput approaches to
identify rare variants, assess copy number, and look for
epigenetic variables such as DNA methylation, the field
should soon have a more comprehensive view of the genetic
basis of BP.
Each of these powerful approaches has both strengths and
weaknesses, but taken together, they should continue to
rapidly advance our understanding of the mechanisms
underlying renal control of BP.
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